Evidence Summary
- Evidence Level
- Preliminary
- Mechanism
- Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Immunomodulatory
- Safety
- Excellent safety profile. GI upset (nausea, vomiting, diarrhea) at high doses. Rare bronchospasm with inhalation. Safe in pregnancy at standard doses.
- Dosing
- 600–1800 mg/day divided doses (e.g. 600 mg TID); durations in studies 4–12 weeks.
NAC 600-1800mg/day. Glutathione/antioxidant support; studied for fatigue/oxidative stress in Long COVID/ME-CFS. Good safety profile; small positive studies.
Clinical Trials
4 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT05371288 | The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19 | Early phase 1 | Withdrawn |
| NCT04542161 | Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Phase 2 | Active, not recruiting |
| NCT03502044 | New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fa | Not applicable | Unknown status |
| NCT01154647 | Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes | Not applicable | Unknown status |